Susquehanna International Group’s Cogent Biosciences COGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$17.5M Buy
453,500
+241,900
+114% +$8.93M ﹤0.01% 2396
2025
Q4
$7.52M Buy
211,600
+12,500
+6% +$351K ﹤0.01% 3431
2025
Q3
$2.86M Buy
199,100
+101,500
+104% +$1.2M ﹤0.01% 5070
2025
Q2
$701K Buy
+97,600
New +$541K ﹤0.01% 8350
2025
Q1
Sell
-12,800
Closed -$99.8K 12586
2024
Q4
$99.8K Sell
12,800
-2,200
-15% -$21.9K ﹤0.01% 11351
2024
Q3
$162K Sell
15,000
-20,100
-57% -$196K ﹤0.01% 10669
2024
Q2
$296K Sell
35,100
-12,700
-27% -$96.3K ﹤0.01% 9478
2024
Q1
$321K Buy
47,800
+11,600
+32% +$71.7K ﹤0.01% 9560
2023
Q4
$213K Buy
36,200
+19,500
+117% +$149K ﹤0.01% 10562
2023
Q3
$163K Buy
+16,700
New +$198K ﹤0.01% 10458
2023
Q1
Sell
-22,200
Closed -$257K 12657
2022
Q4
$257K Sell
22,200
-22,800
-51% -$283K ﹤0.01% 9487
2022
Q3
$671K Sell
45,000
-1,800
-4% -$24.7K ﹤0.01% 7683
2022
Q2
$422K Buy
+46,800
New +$319K ﹤0.01% 8688

Other funds holding COGT

Susquehanna International Group's COGT Position: Q1 2026 in Review

Susquehanna International Group reduced its Cogent Biosciences (COGT) stake by 75% in Q1 2026, selling an estimated $7.87M and leaving 70,478 shares worth $2.71M. The position accounts for ﹤0.01% of the portfolio, ranked #5486.

Susquehanna International Group first reported a position in COGT in Q3 2018 and has held it in 19 quarters since. The position peaked at $10.1M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Susquehanna International Group held 70,478 shares of Cogent Biosciences worth $2.71M as of Q1 2026.
  • Susquehanna International Group sold 213,019 Cogent Biosciences shares in Q1 2026, an estimated $7.87M.
  • Cogent Biosciences made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5486 holding.
  • Susquehanna International Group first reported a position in Cogent Biosciences in Q3 2018 and has held it in 19 quarters since.
  • Susquehanna International Group's Cogent Biosciences position peaked at $10.1M in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.